Skip to main navigation Skip to search Skip to main content

Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder

Research output: Contribution to journal › Article › peer-review

Abstract

We report a case of treatment-resistant obsessive-compulsive disorder (OCD) that was successfully treated with a pharmacological augmentation of topiramate plus paroxetine. The patient, a 45-year-old woman, was on a stable dose of paroxetine (40 mg/day) when she was started on topiramate (up to 150 mg/day). After 9 weeks of this treatment, her clinical condition remarkably improved, as indicated by a significant decrease of the evaluation scales (Yale-Brown Obsessive-Compulsive Scale and Clinical Global Impression Scale). Our case suggests that topiramate might be beneficial in augmentation with selective serotonin reuptake inhibitors in patients with treatment-resistant OCD, although further investigations are warranted to confirm our findings.

Original languageEnglish (US)
Pages (from-to)189-191
Number of pages3
JournalInternational Clinical Psychopharmacology
Volume21
Issue number3
DOIs
StatePublished - May 2006
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Augmentation
  • Obsessive-compulsive disorder
  • Paroxetine
  • Topiramate
  • Treatment-resistant

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder'. Together they form a unique fingerprint.

Cite this